This week’s three IPOs raised a combined $263 million. Continuing a streak of outperformance from larger IPOs, contract research organization Medpace led with a 21% gain, while Protagonist Therapeutics was the latest biotech IPO to break issue. ...read more
Medpace Holdings, a global full-service CRO focused on small and mid-sized biopharmaceuticals, raised $161 million by offering 7 million shares at $23, the high end of the range of $20 to $23. Medpace Holdings plans to list on the Nasdaq under the symbol MEDP....read more
Four companies are set to raise a combined $270 million in the week ahead. Most notable deal Medpace, a contract research organization focused on biotechs, is joined by two potential customers: Protagonist Therapeutics and Motif Bio. Thanks to insider support,...read more
inVentiv Group Holdings, one of the largest global contract research organizations, withdrew its plans for an initial public offering on Wednesday. It originally filed in April 2016 with an estimated deal size of $500 million.
inVentiv withdrew after Advent...read more
US IPO Weekly Recap: Medpace leads week's three IPOs
This week’s three IPOs raised a combined $263 million. Continuing a streak of outperformance from larger IPOs, contract research organization Medpace led with a 21% gain, while Protagonist Therapeutics was the latest biotech IPO to break issue. ...read more
Picking up the pace: Global CRO Medpace prices IPO at $23, the high end of the range
Medpace Holdings, a global full-service CRO focused on small and mid-sized biopharmaceuticals, raised $161 million by offering 7 million shares at $23, the high end of the range of $20 to $23. Medpace Holdings plans to list on the Nasdaq under the symbol MEDP....read more
US IPO Week Ahead: Medpace and three others are on pace for IPOs
Four companies are set to raise a combined $270 million in the week ahead. Most notable deal Medpace, a contract research organization focused on biotechs, is joined by two potential customers: Protagonist Therapeutics and Motif Bio. Thanks to insider support,...read more
Company reinvents itself: inVentiv Group withdraws estimated $500 million IPO
inVentiv Group Holdings, one of the largest global contract research organizations, withdrew its plans for an initial public offering on Wednesday. It originally filed in April 2016 with an estimated deal size of $500 million. inVentiv withdrew after Advent...read more